SECTION 1: REMAP-CAP SIMVASTATIN DOMAIN INTERVENTIONS

This domain aims to determine the effectiveness of simvastatin for patients with suspected or confirmed COVID-19. In this domain, patients are randomised to receive:

- No simvastatin (no placebo)
- Simvastatin

SECTION 2: NO SIMVASTATIN INTERVENTION

**Intervention**
Patients allocated to the *no simvastatin* intervention should not receive any statin for the treatment of SARS-CoV-2 infection.

**Duration of intervention**
Withholding of any statin for the treatment of COVID-19 is to continue until the end of study day 28 or hospital discharge, whichever occurs first. For patients admitted to an ICU, administration of any statin for the treatment of COVID-19 after ICU discharge will *not* be considered to be a protocol deviation.

SECTION 3: SIMVASTATIN INTERVENTION

**Intervention**
Simvastatin 80mg will be administered once daily for 28 days or until hospital discharge, whichever occurs first.

**Dosing**
Simvastatin 80mg will be administered once daily by the enteral route. If the patient has a nasogastric, orogastric, percutaneous enterogastric (PEG) or percutaneous enterojejunal (PEJ) tube, simvastatin can be crushed and mixed with 20ml sterile water and flushed down the tube. To ensure that the feeding tube is not blocked, a further 20ml sterile water should be flushed down following administration of simvastatin.

**Duration of intervention**
Simvastatin 80mg will be administered once daily until ICU discharge or study day 28, whichever occurs first. For patients admitted to ICU, simvastatin may be discontinued at ICU discharge. If the patient is readmitted to ICU prior to the end of study day 28, it is not required to recommence administration of simvastatin.

The first dose of the study drug will be administered as soon as possible after assignment, ideally within four hours of randomization and subsequent doses will be given each morning starting on the following calendar study day. If for any reason a dose is not administered at the intended time, it should be administered subsequently but not more than 12 hours after the intended time of administration.

If a single dose of amiodarone (intravenous infusion of not more than one hour or any enteral dose) is administered no change is required for simvastatin dose. If a patient received more than a single dose of amiodarone, simvastatin dose should be reduced to 20mg daily.

Omission of two or more consecutive doses of simvastatin will be considered a protocol deviation.

**Discontinuation of study drug**
Simvastatin should be discontinued if there is development of a serious adverse event related to simvastatin (Elevated Creatine Kinase more than 10 times the upper limit of normal, Alanine Transaminase or Aspartate Transaminase more than 8 times the upper limit of normal). Simvastatin can also be discontinued at any time by the treating clinician if doing so is regarded as being in the best interests of the patient.
SECTION 4: CONCOMITANT CARE

All treatment that is not specified by assignment within the platform will be determined by the treating clinician.